Patents Assigned to Amgen
  • Polynucleotides encoding myostatin binding agents
    Patent number: 7803923
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 28, 2010
    Assignee: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas C. Boone
  • c-MET kinase binding proteins
    Patent number: 7803907
    Abstract: Polypeptides comprising monomer domains that bind to c-MET, or portions thereof, are provided.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: September 28, 2010
    Assignee: Amgen Mountain View, Inc.
    Inventors: Willem P. C. Stemmer, D. Victor Perlroth, Sanjeev Satyal, Benjamin M. Alba, Alice Bakker, Amy N. Duguay, Qiang Liu, Joshua Silverman, Richard Smith, Candace Swimmer
  • Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
    Patent number: 7803809
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: September 28, 2010
    Assignee: Amgen Inc.
    Inventors: Russell Graceffa, Matthew Kaller, Daniel La, Patricia Lopez, Vinod F. Patel, Wenge Zhong
  • OSK1 peptide analogs and pharmaceutical compositions
    Patent number: 7803769
    Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: September 28, 2010
    Assignee: Amgen Inc.
    Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
  • Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
    Patent number: 7799795
    Abstract: Provided herein are compounds of the formula where A1, A2, A3, A4, L, Q, R1, R2, R3, R4, Rx, Ry, Rz, X, Y1, Y2, Y4 and Z are as described herein, and compositions thereof that are useful in the treatment of inflammatory and immune conditions and diseases. In particular, the invention provides aryl nitrile compounds which modulate the expression and/or function of a chemokine receptor.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: September 21, 2010
    Assignee: Amgen Inc.
    Inventors: Philippe Bergeron, Xiaoqi Chen, Xiaohui Du, Jeffrey Deignan, Jason A. Duquette, Darin Gustin, Julio C. Medina, Jeffrey T. Mihalic, George R. Tonn
  • BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20100234373
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, L, R1, R2 and R3 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 16, 2010
    Applicant: Amgen Inc.
    Inventors: Erin F. Dimauro, Jean E. Bemis, Stuart C. Chaffee, Ning Chen, Essa Hu, Roxanne Kunz, Matthew W. Martin, David C. McGowan, Shannon Rumfelt
  • Benzomorpholine derivatives and methods of use
    Patent number: 7795254
    Abstract: Selected benzomorpholine compounds, including 7-((6,7-bis(methyloxy)-4-quinolinyl)oxy)-N-(5 -methyl-3-isoxazolyl)-2,3-dihydro-4H-1,4-benzoxazine-4-carboxamide, are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: October 28, 2008
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: Jean-Christophe Harmange, Matthew W. Martin, Yohannes Teffera, Raju Subramanian, Ryan White, Roger Zanon, Jay Larrow, Joseph F. Payack, Mina Dilmeghani Seran
  • Method for generating F(ab?)2 antibody fragments
    Patent number: 7794970
    Abstract: Methods for generating F(ab?)2 fragments from antibodies using thermolysin as well as F(ab?)2 fragments and compositions comprising F(ab?)2 fragments generated by the method are described.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: September 14, 2010
    Assignee: Amgen Inc.
    Inventors: John O. Hui, Mitsuru Haniu, Hsieng Sen Lu
  • Nucleic acids encoding human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
    Patent number: 7795413
    Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
    Type: Grant
    Filed: June 22, 2007
    Date of Patent: September 14, 2010
    Assignee: Amgen, Inc.
    Inventors: Kenneth D. Wild, Jr., James J. S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
  • Homogeneous Antibody Populations
    Publication number: 20100226925
    Abstract: The present invention is generally directed to methods of producing an increase in the enrichment and/or recovery of preferred forms of monoclonal antibodies. More particularly, the invention relates to methods for eliminating disulfide heterogeneity in the hinge region of recombinant IgG2 antibody proteins.
    Type: Application
    Filed: September 11, 2008
    Publication date: September 9, 2010
    Applicant: AMGEN INC.
    Inventors: Thomas M. Dillon, Pavel Bondarenko, Jette Wypych, Martin J. Allen, Alain Balland, Margaret Speed Ricci, Amy Guo, Wenyan Shen, Jeonghoon Sun, Chris Vezina
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7790674
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Pharmaceutical formulations
    Patent number: 7790679
    Abstract: A method of stabilizing an aqueous protein or antibody formulation is disclosed herein. Additionally, stable pharmaceutical formulations are contemplated which comprise a biologically active protein, a destabilizing concentration of preservative and a stabilizing concentration of osmolyte.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Tiansheng Li, Christopher J. Sloey
  • Human anti-IFN-? neutralizing antibodies as selective IFN-? pathway inhibitors
    Patent number: 7790859
    Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
  • METHOD FOR CULTURING MAMMALIAN CELLS TO IMPROVE RECOMBINANT PROTEIN PRODUCTION
    Publication number: 20100221823
    Abstract: The present invention relates to methods for mammalian cell culture, wherein the methods make use of media containing polyamines, such as putrescine, spermidine and spermine.
    Type: Application
    Filed: June 10, 2008
    Publication date: September 2, 2010
    Applicant: Amgen Inc.
    Inventors: Rebecca E. McCoy, Arvia E. Morris
  • Aminopyrimidine compounds and methods of use
    Patent number: 7786132
    Abstract: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: August 31, 2010
    Assignee: Amgen Inc.
    Inventors: Adrian Leonard Smith, Paul Edward Brennan, Frenel Fils DeMorin, Gang Liu, Nick A. Paras, Daniel Martin Retz, Elizabeth Rainbeau
  • Polynucleotides encoding IL-17 receptor A antigen binding proteins
    Patent number: 7786284
    Abstract: The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: August 31, 2010
    Assignee: Amgen Inc.
    Inventors: Joel Tocker, Jacques J. Peschon, James F. Smothers
  • IL-6 binding proteins
    Patent number: 7786262
    Abstract: Polypeptides comprising monomer domains that bind to IL-6, or portions thereof, are provided.
    Type: Grant
    Filed: July 12, 2006
    Date of Patent: August 31, 2010
    Assignee: Amgen Mountain View Inc.
    Inventors: Alice Bakker, Amy N. Duguay, Qiang Liu, Joshua Silverman, Kevin Moore
  • NOVEL PROTEINS WITH TARGETED BINDING
    Publication number: 20100216663
    Abstract: Methods for identifying discrete monomer domains and immuno-domains with a desired property are provided. Methods for generating multimers from two or more selected discrete monomer domains are also provided, along with methods for identifying multimers possessing a desired property. Presentation systems are also provided which present the discrete monomer and/or immuno-domains, selected monomer and/or immuno-domains, multimers and/or selected multimers to allow their selection. Compositions, libraries and cells that express one or more library member, along with kits and integrated systems, are also included in the present invention.
    Type: Application
    Filed: December 3, 2009
    Publication date: August 26, 2010
    Applicant: AMGEN MOUNTAIN VIEW INC.
    Inventors: JOOST A. KOLKMAN, WILLEM P.C. STEMMER
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20100209435
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: February 15, 2010
    Publication date: August 19, 2010
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Heteroaryl-substituted alkyne compounds and method of use
    Patent number: 7776869
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A1, A2, A3, A4, R1 and R2 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: August 17, 2010
    Assignee: Amgen Inc.
    Inventors: Stuart C. Chaffee, Brian K. Albrecht, Brian L. Hodous, Matthew W. Martin, David C. McGowan, Erin F. DiMauro, Gade Reddy, Victor J. Cee, Philip R. Olivieri, Anthony Reed, Karina Romero